Slide 1: First nine months results
2014 First nine months results CONFERENCE CALL – 28 OCTOBER 2014
Slide 2: First nine months 2014 highlights
First nine months 2014 highlights • Revenue € 742,1 million, up 5,7% • EBITDA € 212.9 million or 28,7% of sales, up 22,4% • Operating income (EBIT) € 180,4 million or 24.3% of sales, up 21,6% • Net income € 124.0 million or 16.7% of sales, up 22,2% • Exclusive license for Vitaros® from Apricus Biosc
Slide 3: Main product sales
Main product sales Corporate products including drugs for rare diseases account for 51.4% of revenue (million Euro) Jan‐Sep 2014 Jan‐Sep 2013 Change % Zanidip® (lercanidipine) 86.1 86.2 (0.1) Zanipress® (lercanidipine+enalapril) 46.4 42.9 8.3 Urorec® (silodosin) 42.7 34.1 25.3 Livazo® (pitavastatin)
Slide 4: A diversified product portfolio
A diversified product portfolio Drugs for rare diseases 12.4% Other corporate products 10.3% Livazo 2.5% Urorec 5.8% OTC 17.3% Zanipress 6.3% Subsidiaries’ local product Zanidip 11.6% portfolios 29.3% Methadone ‐ France 3% Peptazol® (pantoprazole) ‐ Italy 3% Pharmaceutical chemicals 3.3% Entact® (es
Slide 5: Composition of revenue by geography
Composition of revenue by geography New products and new markets drive growth (million Euro) Jan‐Sep 2014 Jan‐Sep 2013 Change % Italy 165.6 168.6 (1.8) France 81.4 85.0 (4.2) Germany 61.8 58.1 6.4 Russia, other CIS countries and Ukraine 60.0 66.1 (9.1) Spain 56.0 23.4 139.5 Turkey 49.9 49.7 0.4 U.S.
Slide 6: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical revenue Other international sales 14.9% (sales to licensees and exports) Italy 23.1% Other W. Europe 2.5% Other CEE 2,8% Portugal 3.7% North Africa 4.0% U.S.A. 5.9% France 11.3% Turkey 7.0% Germany 8.6% Spain 7.8% Russia, other CIS and Ukraine 8.4% Data: Firs
Slide 7: First nine months 2014 results
First nine months 2014 results Significant margin growth (million Euro) Jan‐Sep 2014 Jan‐Sep 2013 Change % Revenue 742.1 702.0 5.7 Gross Profit 497.3 460.1 8.1 as % of revenue 67.0 65.5 SG&A Expenses 253.3 244.9 3.5 as % of revenue 34.2 34.8 R&D Expenses 62.0 55.4 11.9 as % of revenue 8.3 7.9 Other
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 30 Sep 2014 31 Dec 2013 Change Cash and short‐term financial 241.6 52.3 189.3 investments Bank overdrafts and short‐term loans (32.5) (34.0) 1.5 Loans – due within one year (94.4) (82.5) (11.9) Loans – due after one year (267.2) (196.8) (70.
Slide 9: 2014 Outlook
2014 Outlook Objectives • Consolidated sales slightly below € 1 billion, including a significant negative currency effect in addition to Adagen® and Entact® license terminations. • Margin improvement • EBIT to be of around € 230 million • Net Income to be of around € 160 million • No new acquisition
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finan